DR. ANDREW D. LEAVITT M.D.
Prescription History 1952343113
Internal Medicine - Hematology in San Francisco, CA


Quality Rating: 74.46 out of 100 score

NPI Status: Active since June 12, 2006

Contact Information

505 PARNASSUS AVE
SAN FRANCISCO, CA
ZIP 94143
Phone: (415) 514-3432
Fax: (415) 514-3433

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. ANDREW D. LEAVITT M.D., an active Hematology specialist practicing in San Francisco, CA. Our medical registry currently tracks 7 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 230 documented patient claims. Among these therapy options, the most frequently utilized medication is Eliquis, which accounts for 86 claims alone.

Medication Index


Ayvakit

Generic Formulation: AvapritinibSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
CA State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.3
Peer Average Days Supply520
Conservative Utilization

This provider writes prescriptions for this formulation 29.4% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $449,161.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$37,430.15

State Avg Cost Per Claim

$37,306.13

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat a certain type of stomach, bowel, or esophagus cancer (gastrointestinal stromal tumor-GIST). Avapritinib is also be used to treat a certain immune system disorder (advanced systemic mastocytosis). Avapritinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells and certain immune system cells (mast cells).

Eliquis

Generic Formulation: ApixabanSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 86
30-Day Fills 170.0
Days Supply 5,100
CA State Average Benchmarks
Peer Average Claims68.0
Peer Average 30-Day Fills112.8
Peer Average Days Supply3,201
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 26.5% more claims than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $97,043.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,128.41

State Avg Cost Per Claim

$848.49

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Hydroxyurea

Generic Formulation: HydroxyureaSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 24
30-Day Fills 41.3
Days Supply 1,162
CA State Average Benchmarks
Peer Average Claims33.0
Peer Average 30-Day Fills69.5
Peer Average Days Supply2,062
Conservative Utilization

This provider writes prescriptions for this formulation 27.3% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $776.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$32.34

State Avg Cost Per Claim

$42.36

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.

Therapeutic Applications

This medication is used by people with sickle cell anemia to reduce the number of painful crises caused by the disease and to reduce the need for blood transfusions. Some brands are also used to treat certain types of cancer (such as chronic myelogenous leukemia, squamous cell carcinomas).

Promacta

Generic Formulation: Eltrombopag OlamineSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 45
30-Day Fills 47.0
Days Supply 1,406
CA State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills19.1
Peer Average Days Supply566
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 150.0% higher than the standard regional baseline profile for CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $606,774.66 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,483.88

State Avg Cost Per Claim

$12,055.64

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat low platelet levels in people who have a certain blood disorder called chronic immune (idiopathic) thrombocytopenia purpura (ITP) or who have chronic hepatitis C. It may also be used to treat people with a certain blood disorder (aplastic anemia). Platelets are a type of blood cell needed to form blood clots and prevent bleeding. Eltrombopag decreases your risk of bleeding by increasing the number of platelets. Eltrombopag acts like a certain natural substance (thrombopoietin) that causes the body to produce platelets.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 21.3
Days Supply 580
CA State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills27.8
Peer Average Days Supply371
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.0% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $65.23 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.44

State Avg Cost Per Claim

$5.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Tranexamic Acid

Generic Formulation: Tranexamic AcidSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 12
30-Day Fills 28.0
Days Supply 757
CA State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills25.3
Peer Average Days Supply343
Conservative Utilization

This provider writes prescriptions for this formulation 47.8% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,026.84 across this reporting matrix range.

Provider Avg Cost Per Claim

$585.57

State Avg Cost Per Claim

$105.28

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Antifibrinolytic hemostatic used in severe hemorrhage.

Xarelto

Generic Formulation: RivaroxabanSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 39
30-Day Fills 73.0
Days Supply 2,190
CA State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills79.1
Peer Average Days Supply2,270
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $42,718.55 across this reporting matrix range.

Provider Avg Cost Per Claim

$1,095.35

State Avg Cost Per Claim

$907.01

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.

Therapeutic Applications

Rivaroxaban is used to prevent blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip or knee replacement surgery. It is also used to prevent blood clots from forming in high-risk patients with limited mobility during their hospital stay and after discharge. In addition, rivaroxaban is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and to prevent the blood clots from forming again. Rivaroxaban may be used in children to prevent blood clots from forming after a certain heart surgery (Fontan procedure). Rivaroxaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. ANDREW D. LEAVITT M.D. provides transparency into local medical care patterns within San Francisco, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.